2021
Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations
Heinrichs D, Brandt EF, Fischer P, Köhncke J, Wirtz TH, Guldiken N, Djudjaj S, Boor P, Kroy D, Weiskirchen R, Bucala R, Wasmuth HE, Strnad P, Trautwein C, Bernhagen J, Berres ML. Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. Cells 2021, 10: 252. PMID: 33525493, PMCID: PMC7918903, DOI: 10.3390/cells10020252.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkersCell PolarityDietDisease ProgressionFibrosisGene Expression RegulationHepatic Stellate CellsHepatocytesHumansLiverMacrophage Migration-Inhibitory FactorsMaleMice, Inbred C57BLModels, BiologicalNatural Killer T-CellsNon-alcoholic Fatty Liver DiseaseReceptors, ImmunologicConceptsMacrophage migration inhibitory factorNon-alcoholic fatty liver diseaseNAFLD progressionLiver fibrogenesisNKT cell populationNKT cell subpopulationsChronic liver injuryFatty liver diseaseNon-alcoholic steatohepatitisAnti-fibrotic propertiesPro-fibrotic effectsMigration inhibitory factorPleiotropic inflammatory cytokineLiver injury modelPro-fibrotic phenotypeMIF expressionMurine resultsNASH patientsNKT cellsLiver injuryLiver diseaseFibrosis markersInflammatory cytokinesDiet feedingInjury model
1995
Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes
Beisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes. Diabetes 1995, 44: 824-829. PMID: 7789650, DOI: 10.2337/diab.44.7.824.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsEnzyme-linked immunosorbent assayAlbumin excretionDuration of diabetesElevated levelsNormal renal statusTissue advanced glycosylation end productsDiabetic vascular complicationsTissue AGE levelsGlycosylation end productsEvident retinopathyMicroalbuminuric phaseOvert microangiopathySevere retinopathyVascular complicationsDiabetic nephropathyRenal statusUrinary albuminProliferative retinopathyEarly retinopathyHigher age levelsSignificant elevationRetinopathyRetinal diseasesEarly manifestation
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes